Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

77.92CHF
4:31pm BST
Change (% chg)

CHF0.89 (+1.16%)
Prev Close
CHF77.03
Open
CHF77.03
Day's High
CHF78.38
Day's Low
CHF76.96
Volume
7,218,304
Avg. Vol
5,324,504
52-wk High
CHF96.20
52-wk Low
CHF71.84

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.10
Market Cap(Mil.): CHF197,447.00
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.85
Yield (%): 3.63

Financials

  NOVN.S Industry Sector
P/E (TTM): 14.10 62.58 62.94
EPS (TTM): 5.46 -- --
ROI: 11.19 12.13 11.75
ROE: 16.51 13.07 12.58

BRIEF-Rapha Capital Management Says Participated In A Series C Financing For Poseida Therapeutics

* RAPHA CAPITAL MANAGEMENT, LLC - PARTICIPATION IN A SERIES C FINANCING FOR POSEIDA THERAPEUTICS

22 Apr 2019

Second death in Novartis gene therapy trials under investigation

Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

20 Apr 2019

Second death in Novartis gene therapy trials under investigation

April 19 Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

20 Apr 2019

BRIEF-Novartis AG Says Avexis Data Reinforce Effectiveness Of Zolgensma In Treating SMA Type 1

* AVEXIS DATA REINFORCE EFFECTIVENESS OF ZOLGENSMA® IN TREATING SPINAL MUSCULAR ATROPHY (SMA) TYPE 1

17 Apr 2019

BRIEF-Novartis Announces FDA Filing Acceptance & Priority Review Of Brolucizumab For Patients With Wet AMD

* NOVARTIS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF BROLUCIZUMAB (RTH258) FOR PATIENTS WITH WET AMD

15 Apr 2019

Stadler Rail jumps to first-day premium after Swiss flotation

ZURICH Shares in Stadler Rail surged on Friday as investors piled in to an oversubscribed initial public offering (IPO) that valued the Swiss trainmaker at around $3.8 billion and made more than a billion Swiss francs for Chairman Peter Spuhler.

12 Apr 2019

UPDATE 3-Stadler Rail jumps to first-day premium after Swiss flotation

* Chairman Peter Spuhler sells 35 mln shares worth 1.33 bln francs

12 Apr 2019

Stadler Rail IPO issue price set at 38 Sfr per share - source

ZURICH, April 11 Stadler Rail's initial public offering issue price has been set at 38 Swiss francs per share, a source said, near the upper end of the company's 33-44 franc range, as the Swiss trainmaker prepares to begin trading on the SIX Swiss Exchange on Friday.

11 Apr 2019

BRIEF-Novartis' Sandoz Strikes Deal To Commercialize Constipation Treatment

* SANDOZ DRIVES DIFFERENTIATED PORTFOLIO WITH DEAL TO COMMERCIALIZE NEW TREATMENT FOR OPIOID-INDUCED CONSTIPATION IN KEY EUROPEAN COUNTRIES

11 Apr 2019

Alcon tops $28 billion market cap in decade's biggest Swiss stock deal

ZURICH Swiss eyecare company Alcon made its debut on the SIX Swiss Exchange on Tuesday with a market capitalisation of more than $25 billion after a shareholder spin-off from drugmaker Novartis, the Alpine nation's biggest stock deal in a decade.

09 Apr 2019

Earnings vs. Estimates